ArticleFrontiers in medicine2026

Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China.

Xi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.